In a clinical study a high-dose chemotherapy (HDCT) regimen was investigated as a treatment option in germ cell cancer patients who did not benefit from one or multiple cycles of conventional chemotherapy [1] . The therapy regimen comprised a combination of carboplatin, etoposide and thiotepa in total doses of up to 1,500, 2,400 and 750 mg/m 2 , respectively, and a myelosupportive treatment comprising an autologous stem cell rescue (ASCR) retransfusing with retransfusion of CD34 + cells on day seven of the HDCT and administration of granulocyte colony-stimulating factor starting on day eight. The objective of this population pharmacokinetic analysis was the pharmacokinetic (PK) characterization of the three cytotoxic drugs in the setting of HDCT and the assessment of the remaining cytotoxic drug concentrations on the day of the ASCR.
Objectives
In a clinical study a high-dose chemotherapy (HDCT) regimen was investigated as a treatment option in germ cell cancer patients who did not benefit from one or multiple cycles of conventional chemotherapy [1] . The therapy regimen comprised a combination of carboplatin, etoposide and thiotepa in total doses of up to 1,500, 2,400 and 750 mg/m 2 , respectively, and a myelosupportive treatment comprising an autologous stem cell rescue (ASCR) retransfusing with retransfusion of CD34 + cells on day seven of the HDCT and administration of granulocyte colony-stimulating factor starting on day eight. The objective of this population pharmacokinetic analysis was the pharmacokinetic (PK) characterization of the three cytotoxic drugs in the setting of HDCT and the assessment of the remaining cytotoxic drug concentrations on the day of the ASCR.
Patients and methods
Carboplatin, etoposide and thiotepa were successively administered as 1 h infusions on three (carboplatin and thiotepa) and four (etoposide) consecutive days. A total of eight, two and thirteen plasma samples after the 1 st , 2 nd and 3 rd carboplatin infusion, respectively, were collected for PK analysis. Ultrafilterable platinum concentrations were determined via flameless atomic absorption spectrometry [1] , etoposide and thiotepa concentrations with a modified reversed-phase HPLC and an optimized GC/MS method, respectively [2, 3] . From the 29 patients enrolled in the study data from 19 patients was available for the PK analysis of carboplatin and etoposide and from 17 patients for thiotepa as 2 patients received ifosfamide instead. The patient population was representative for germ cell cancer patients with a median age of 34.9 (5 th -95 th percentile: 22.1 -46.7) years and a body weight of 80.0 (5 th -95 th percentile: 66.2 -101.8) kg. Creatinine clearance revealed a mild renal impairment for some patients (mean: 114.5; 5 th -95 th percentile: 86.4 -165.0 ml/min) leading to a reduction in dose of 20%, 25% and 40% for carboplatin, etoposide and thiotepa, respectively. Data from two patients and one administration was excluded prior to PK analysis of etoposide due to implausibely high and low drug concentrations and a leaking infusion tube. 12.7% of the measured thiotepa concentrations were reported to be below the limit of quantification and were handled according to the M5 method [4] . Despite drug administration as an infusion a delay in the appearance of thiotepa concentrations in the plasma was observed, most probably due to long infusion tubes and therefore a delay model was investigated. All population PK models were developed in NONMEM ® VII.
Results and discussion
Sampling resulted in a median of seven, five and two samples per patient for each application of carboplatin, etoposide and thiotepa, reflecting the fact that the sampling times were originally planned for the PK characterization of carboplatin. The PK for all drugs was best described by linear two compartment disposition models. Estimates for the PK parameters for all drugs were of good precision with a relative standard error < 30% (Tab. 1) and in accordance with those previously published [2, 3, 5] . Creatinine clearance and weight were identified as influential covariates for carboplatin clearance (CL) and the central volume of distribution (V c ), respectively, as previously reported [5] and were integrated into the model by power functions. A correlation between V c and CL of etoposide was allowed during parameter estimation and was quantified with 74.6% (relative standard error: 30.4%, on corresponding variance scale). The delayed appearance of thiotepa in the plasma was considered by a transit model [6] describing the delay by a passage of thiotepa through a chain of transit compartments which was defined by an estimated number of compartments (N) and the mean passage time (MPT). Due to model stability thiotepa concentration entered the model logarithmically transformed. The predictive performance of the models was assessed by a visual predictive check (data not shown) comparing the 10 th , 50 th and 90 th percentile of 1,000 simulated concentration-time profiles with those of the observed data. The visual predictive check showed an adequate prediction of the variability (80% prediction interval) and the central tendency (median) without any systematic deviation.
After ASCR the CD34 + cells migrate from the blood to the bone marrow. From a kinetic point of view the central distribution compartment of the drugs comprises the blood, whereas the bone marrow might behave kinetically different, possibly belonging to the peripheral distribution compartment. On the day of ASCR the concentration of etoposide was the most relevant (central/peripheral compartment: 0.25/1.70 µg/ml) compared to the negligible concentrations of ultrafilterable platinum (0.02/0.2 µg/ml) and thiotepa (1.4 × 10 -4 /1.5 × 10 -3 µg/ml) for a typical patient receiving median doses of carboplatin, etoposide and thiotepa. For etoposide the EC 50 value for the inhibition of proliferation of hematopoietic progenitor cells is 0.97 µg/ml [7] . Hence, with regard to the concentration of etoposide in the central distribution compartment on the day of ASCR, day seven represents the adequate day for the ASCR from a pharmacokinetic perspective.
Conclusions
The pharmacokinetics of carboplatin, etoposide and thiotepa in a HDCT regimen were successfully characterized. Individual pharmacokinetic parameter estimates for each drug will be used together with information on leukocyte counts to characterize myelosuppression with a semi-mechanistic pharmacokinetic/pharmacodynamic model. The optimal day for an ASCR will then be evaluated not only based on the pharmacokinetics of the drugs but also considering the pathophysiological state of the impaired leukopoiesis during HDCT. 
